Literature DB >> 32588893

Renal pathology in a mouse model of severe Spinal Muscular Atrophy is associated with downregulation of Glial Cell-Line Derived Neurotrophic Factor (GDNF).

Hazel Allardyce1,2, Daniela Kuhn3, Elena Hernandez-Gerez1,2, Niko Hensel3,4, Yu-Ting Huang2,5, Kiterie Faller2,5, Thomas H Gillingwater2,5, Fabio Quondamatteo6, Peter Claus3,4, Simon H Parson1,2.   

Abstract

Spinal muscular atrophy (SMA) occurs as a result of cell-ubiquitous depletion of the essential survival motor neuron (SMN) protein. Characteristic disease pathology is driven by a particular vulnerability of the ventral motor neurons of the spinal cord to decreased SMN. Perhaps not surprisingly, many other organ systems are also impacted by SMN depletion. The normal kidney expresses very high levels of SMN protein, equivalent to those found in the nervous system and liver, and levels are dramatically lowered by ~90-95% in mouse models of SMA. Taken together, these data suggest that renal pathology may be present in SMA. We have addressed this using an established mouse model of severe SMA. Nephron number, as assessed by gold standard stereological techniques, was significantly reduced. In addition, morphological assessment showed decreased renal vasculature, particularly of the glomerular capillary knot, dysregulation of nephrin and collagen IV, and ultrastructural changes in the trilaminar filtration layers of the nephron. To explore the molecular drivers underpinning this process, we correlated these findings with quantitative PCR measurements and protein analyses of glial cell-line-derived neurotrophic factor, a crucial factor in ureteric bud branching and subsequent nephron development. Glial cell-line-derived neurotrophic factor levels were significantly reduced at early stages of disease in SMA mice. Collectively, these findings reveal significant renal pathology in a mouse model of severe SMA, further reinforcing the need to develop and administer systemic therapies for this neuromuscular disease.
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Year:  2020        PMID: 32588893     DOI: 10.1093/hmg/ddaa126

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  7 in total

Review 1.  The phospho-landscape of the survival of motoneuron protein (SMN) protein: relevance for spinal muscular atrophy (SMA).

Authors:  Nora Tula Detering; Tobias Schüning; Niko Hensel; Peter Claus
Journal:  Cell Mol Life Sci       Date:  2022-08-25       Impact factor: 9.207

Review 2.  Spinal muscular atrophy: Broad disease spectrum and sex-specific phenotypes.

Authors:  Natalia N Singh; Shaine Hoffman; Prabhakara P Reddi; Ravindra N Singh
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-01-05       Impact factor: 5.187

3.  Dual SMN inducing therapies can rescue survival and motor unit function in symptomatic ∆7SMA mice.

Authors:  Kaitlyn M Kray; Vicki L McGovern; Deepti Chugh; W David Arnold; Arthur H M Burghes
Journal:  Neurobiol Dis       Date:  2021-08-20       Impact factor: 5.996

Review 4.  Metabolic and Nutritional Issues Associated with Spinal Muscular Atrophy.

Authors:  Yang-Jean Li; Tai-Heng Chen; Yan-Zhang Wu; Yung-Hao Tseng
Journal:  Nutrients       Date:  2020-12-16       Impact factor: 5.717

Review 5.  Protein Network Analysis Reveals a Functional Connectivity of Dysregulated Processes in ALS and SMA.

Authors:  Sabrina Kubinski; Peter Claus
Journal:  Neurosci Insights       Date:  2022-03-28

6.  The Proteome Signatures of Fibroblasts from Patients with Severe, Intermediate and Mild Spinal Muscular Atrophy Show Limited Overlap.

Authors:  Sharon J Brown; Rachel A Kline; Silvia A Synowsky; Sally L Shirran; Ian Holt; Kelly A Sillence; Peter Claus; Brunhilde Wirth; Thomas M Wishart; Heidi R Fuller
Journal:  Cells       Date:  2022-08-23       Impact factor: 7.666

7.  Impairment of the neurotrophic signaling hub B-Raf contributes to motoneuron degeneration in spinal muscular atrophy.

Authors:  Niko Hensel; Federica Cieri; Pamela Santonicola; Ines Tapken; Tobias Schüning; Michela Taiana; Elisa Pagliari; Antonia Joseph; Silke Fischer; Natascha Heidrich; Hella Brinkmann; Sabrina Kubinski; Anke K Bergmann; Manuela F Richter; Klaus Jung; Stefania Corti; Elia Di Schiavi; Peter Claus
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-04       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.